Syncom Formulations (India) Limited

SYNCOMF

INE312C01025

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:51 31/05/2024 pm IST			5-day change	1st Jan Change
11.98 ^INR	-3.31%		-7.35%	-20.35%

17/05	Syncom Formulations Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI
17/05	Syncom Formulations Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI

Syncom Formulations India Ltd Appoints Rinki Bankda as Additional Director, Effective August 13, 2014

August 13, 2014 at 06:25 pm IST

Syncom Formulations India Ltd. has informed that the Board of Directors of the Company at its meeting held on August 13, 2014, has appointed Smt. Rinki Bankda in the category of Women Director as an Additional Director of the Company with effect from August 13, 2014.

Latest news about Syncom Formulations (India) Limited

Syncom Formulations Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	17/05	CI
Syncom Formulations Limited Reports Earnings Results for the Full Year Ended March 31, 2024	17/05	CI
Syncom Formulations Limited Announces Board Changes	29/03	CI
Syncom Formulations Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	14/02	CI
Syncom Formulations Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	08/11	CI
Syncom Formulations Begins Commercial Production at Expanded Plant in Pithampur, India	22/23/22	MT
Syncom Formulations Limited Commences Commercial Production	21/23/21	CI
Syncom Formulations Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/23/14	CI
Syncom Formulations Limited Announces Commercial Production Starts from 30 June 2023	01/23/01	CI
Syncom Formulations Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	29/23/29	CI
Syncom Formulations Limited Reports Earnings Results for the Full Year Ended March 31, 2023	29/23/29	CI
Syncom Formulations Limited Announces Executive Changes	02/23/02	CI
Syncom Formulations Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	13/23/13	CI
Syncom Formulations Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/22/14	CI
Syncom Formulations Limited Approves the Declaration of Dividend for the Financial Year Ended 31 March 2022	20/22/20	CI
Syncom Formulations Sees Delay in Completion of Expansion Project	16/22/16	MT
Syncom Formulations Limited Announces Updates on its Project for Expansion Cum Modernisation of Existing Plant at Pithampur	15/22/15	CI
Syncom Formulations Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	13/22/13	CI
Syncom Formulations Limited Appoints Ruchi Jindal as an Additional Director	28/22/28	CI
Syncom Formulations Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/22/14	CI
Syncom Formulations Limited Announces Executive Changes	13/21/13	CI
Syncom Formulations Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	13/21/13	CI
Syncom Formulations India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	30/21/30	CI
Syncom Formulations Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	12/21/12	CI
Syncom Formulations Limited announced that it has received INR 100.787496 million in funding	25/21/25	CI

Chart Syncom Formulations (India) Limited

Duration

Period

Chart Syncom Formulations (India) Limited

More charts

Company Profile

Syncom Formulations (India) Limited is an India-based company that is engaged in the pharmaceutical business. The Company is engaged in the manufacturing and dealing in pharmaceutical drugs and formulations, and trading of commodities. It is also engaged in the renting of properties. It manufactures and markets a range of pharmaceutical formulations in various dosage forms, such as tablets, capsules, liquids orals, liquid vials and ampoule injections and dry powder injections, ophthalmic preparations, dry syrups and suspensions, ointments, creams, gel, ORS and jelly. The Company's domestic division product categories include Cratus Life Care, Cratus Evolve and Cratus Right Nutrition. Its products include Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Ciprofloxacin Tablets USP 750 mg, Cefazolin For Injection USP 1 gm, Cefotaxime For Injection USP 1 gm, Ceftriaxone for Injection USP 500 mg, Cefuroxime For Injection USP 750 mg and Gentamicin Injection BP 40 mg.

Sector

Pharmaceuticals

Calendar

14/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SYNCOM FORMULATIONS (INDIA) LIMITED	-20.35%	13Cr
ELI LILLY AND COMPANY	+40.73%	74TCr
NOVO NORDISK A/S	+32.83%	60TCr
JOHNSON & JOHNSON	-6.30%	35TCr
MERCK & CO., INC.	+15.15%	32TCr
ABBVIE INC.	+4.05%	28TCr
ASTRAZENECA PLC	+15.00%	24TCr
ROCHE HOLDING AG	-5.52%	21TCr
AMGEN INC.	+6.17%	16TCr
PFIZER, INC.	-0.45%	16TCr